During a live event, Karen Seiter, MD, discussed the role of the JAK/STAT pathway in myeloproliferative neoplasms and the use ...

Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives,” published in the ...

Panelists discuss how managing advanced polycythemia vera requires tailored approaches beyond hydroxyurea when patients show resistance (persistent hematocrit >45%, elevated white blood cell counts, ...

Now, let’s shift our focus to AD. and the emerging role of immune modulators in the treatment of AD. Please discuss the findings presented at AAD 2025 regarding the association of ruxolitinib ...

Though not yet approved, investors are already eyeing the drug as a potential blockbuster. Its commercial rights holder in ...

MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual ...

Today, the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision in Incyte Corp. v. Sun ...

But then again, ruxolitinib has its survival advantage. It’s a great drug for the spleen and symptoms. I tend to start with that in most patients now. I find fedratinib to be very useful in the ...

This week, we take a closer look at two precedential cases concerning pharmaceutical patent protections as applied to drugs in development.

Alopecia universalis (AU) is a rare autoimmune condition that involves complete loss of hair on your face, scalp, and body.